| SHIP2 (INPPL1) is an SH2-domain–containing inositol 5‑phosphatase that hydrolyzes the 5‑phosphate of phosphatidylinositol‑3,4,5‑trisphosphate to generate phosphatidylinositol‑3,4‑bisphosphate, positioning it as a lipid phosphatase that dampens PI3K‑dependent signaling downstream of receptor tyrosine kinases and insulin receptors in metabolically active tissues. The protein contains an N‑terminal SH2 domain that targets SHIP2 to phosphotyrosine‑containing motifs on activated receptors and adaptors, a central catalytic 5‑phosphatase domain responsible for PIP3 dephosphorylation, and C‑terminal proline‑rich regions that mediate interactions with scaffolds and components of endocytic machinery, which allows SHIP2 to integrate both signaling and trafficking functions at the plasma membrane. Genetic disruption in mice shows that loss of SHIP2 increases insulin sensitivity and glucose uptake: SHIP2‑null neonates display severe hypoglycemia and deregulated expression of gluconeogenic genes, and adult heterozygotes exhibit enhanced recruitment of GLUT4 and increased glycogen synthesis in skeletal muscle, consistent with sustained PIP3 levels, augmented Akt phosphorylation, and amplified insulin signal transduction. Liver‑specific inhibition of SHIP2 in hyperglycemic, hyperinsulinemic KKAy mice elevates basal and insulin‑stimulated Akt phosphorylation, reduces expression of glucose‑6‑phosphatase and phosphoenolpyruvate carboxykinase, decreases hepatic gluconeogenesis, and shifts glycogen phosphorylase and glycogen synthase phosphorylation states to favor glycogen accumulation; these changes are accompanied by improved glycolysis, higher hepatic glycogen content, and marked reductions in prandial blood glucose, demonstrating that SHIP2 restrains insulin’s metabolic actions at the level of hepatocyte PIP3 turnover. Across models of diet‑induced obesity and insulin resistance, SHIP2 expression and activity are elevated, and correlate with impaired PI3K–Akt signaling, and pharmacologic SHIP2 inhibition or genetic knockdown exerts insulin‑mimetic effects on glucose metabolism and GLUT1/GLUT4 expression, placing this phosphatase as a central negative regulator of insulin pathway amplitude and a candidate therapeutic target in type 2 diabetes and related metabolic disorders. SHIP2 also modulates FGF‑driven MAPK outputs and receptor tyrosine kinase pathways in vivo, with zebrafish and mammalian data showing that Ship2 attenuates FGF‑dependent gene expression and ERK activation during embryonic patterning, indicating broader roles in RTK signaling beyond metabolic control. Endothelial‑specific manipulation of SHIP2 reveals additional vascular functions: reduced endothelial SHIP2 alters insulin‑stimulated glucose uptake in peripheral tissues and impacts Nox2‑dependent oxidative stress and endothelial dysfunction, linking PI3K lipid phosphatase activity in the endothelium to systemic glucose homeostasis and vascular health. |
